Patents by Inventor Matthias GRIMMLER
Matthias GRIMMLER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12012630Abstract: A method for quantitatively determining the amount of acetaminophen in a sample with greater precision, greater sensitivity and fewer interactions and fewer spectral and chemical interferences with other compounds contained in the sample. The method includes acetaminophen being hydrolyzed and the resulting p-aminophenol being reacted with a compound of general formula (III): in the presence of an oxidant to form a compound of general formula (IV): wherein R1 and R2, independently of one another, are selected from H, —CH3, and —OCH3, R3 is —C2H5 and R4 is a C1-4 alkyl moiety with a terminal sulfonate group, with the proviso that at least one of R1 and R2 is —OCH3 and/or R4 additionally has at least one OH substituent, and then the amount of the compound of general formula (IV) in the reaction mixture being photometrically determined.Type: GrantFiled: January 8, 2019Date of Patent: June 18, 2024Assignee: DiaSys Diagnostic Systems GmbHInventors: Matthias Grimmler, Detlef Thônges, Pia Schu, Carolin Menzenbach, Laura Kreckel
-
Patent number: 11714082Abstract: A method for measuring the presence of calprotectin (S100A8/A) heterodimer in a biological sample using a particle-enhanced turbidimetric immunoassay (PETIA) based on monoclonal antibodies. The method can be adapted on automated standard analyzers and provides a reliable clinical measurement of calprotectin in faecal samples and extracts. The method is comparable to commerical two-site sandwich ELISA. The disclosed method counters spontaneous agglutination caused by calcium ions and low-molecular weight calcium-binding S100 proteins as observed with conventional PETIAs. The method can be used for measuring the presence of human calprotectin in stool, urine, serum, plasma, synovial liquid and other body liquids. Metrological traceability and high commutability with conventional immunoassays (ELISA) has been shown despite of different measurement principles used.Type: GrantFiled: May 9, 2018Date of Patent: August 1, 2023Assignees: Immundiagnostik AG, DiaSys Diagnostic Systems GmbHInventors: Franz-Paul Armbruster, Matthias Grimmler, Pia Schu, Tobias Becker, Felix Walzer
-
Publication number: 20230083766Abstract: A diagnostic reagent that is suitable for turbidimetric analysis with a simple photometer and has high sensitivity for quantitative determination of procalcitonin in a sample is provided. The reagent is an aqueous suspension of polymer particles with antibodies against procalcitonin covalently bound to said polymer particles, in which no or only an extremely slight tendency to agglutination/sedimentation is detectable even after longer standing times and the specific reactivity of the particles remains largely unchanged. The suspended polymer particles have an average particle size in the range from 150 to 450 nm, the suspension includes a proportion of sugar or sugar alcohol dissolved therein in the range from 25 to 250 g/l and the suspension has a pH in the range from 8 to 10.Type: ApplicationFiled: January 25, 2021Publication date: March 16, 2023Applicant: DiaSys Diagnostic Systems GmbHInventors: Matthias GRIMMLER, Thomas MASETTO
-
Publication number: 20210382044Abstract: A method for measuring the presence of calprotectin (S100A8/A) heterodimer in a biological sample using a particle-enhanced turbidimetric immunoassay (PETIA) based on monoclonal antibodies. The method can be adapted on automated standard analyzers and provides a reliable clinical measurement of calprotectin in faecal samples and extracts. The method is comparable to commerical two-site sandwich ELISA. The disclosed method counters spontaneous agglutination caused by calcium ions and low-molecular weight calcium-binding S100 proteins as observed with conventional PETIAs. The method can be used for measuring the presence of human calprotectin in stool, urine, serum, plasma, synovial liquid and other body liquids. Metrological traceability and high commutability with conventional immunoassays (ELISA) has been shown despite of different measurement principles used.Type: ApplicationFiled: May 9, 2018Publication date: December 9, 2021Applicants: Immundiagnostik AG, Diasys Diagnostic Systems GmbHInventors: Franz-Paul Armbruster, Matthias Grimmler, Pia Schu, Tobias Becker, Felix Walzer
-
Publication number: 20200362386Abstract: A method for quantitatively determining the amount of acetaminophen in a sample with greater precision, greater sensitivity and fewer interactions and fewer spectral and chemical interferences with other compounds contained in the sample. The method includes acetaminophen being hydrolyzed and the resulting p-minophenol being reacted with a compound of general formula (III) in the presence of an oxidant, wherein R1 and R2, independently of one another, are selected from H, —CH3, and —OCH3, R3 is —C2H5 and R4 is a C1-4 alkyl moiety with a terminal sulfonate group, with the proviso that at least one of R1 and R2 is —OCH3 and/or R4 additionally has at least one OH substituent, and then the amount of the compound of general formula (IV) in the reaction mixture being photometrically determined.Type: ApplicationFiled: January 8, 2019Publication date: November 19, 2020Applicant: DiaSys Diagnostic Systems GmbHInventors: Matthias GRIMMLER, Detlef THÖNGES, Pia SCHU, Carolin MENZENBACH, Laura KRECKEL
-
Patent number: 10202632Abstract: A method for determining the amount of glycated hemoglobin (HbA1c), in which—if required—the erythrocytes in a sample are hemolyzed, the haemoglobin that is then released—if required—is contacted with a proteolytic agent and the glycated hemoglobin degradation products obtained in this way or otherwise are quantified is disclosed. In order to provide such a process and reagents employable therein that has/have the property of sufficient stability of the chemical compounds that are essential to the reaction, the provision of the requisite proteolytic agent in the form of an inactivated protease is proposed, which is then only reactivated in situ.Type: GrantFiled: March 31, 2015Date of Patent: February 12, 2019Assignee: DiaSys Diagnostic Systems GmbHInventors: Günther Gorka, Yoshifumi Watazu, Erwin Metzmann, Alexandra Lein, Holger Müller, Matthias Grimmler
-
Patent number: 10093959Abstract: A method for determining the amount of glycated haemoglobin (HbA1c), in which—if required—the erythrocytes in a sample are haemolysed, the haemoglobin that is then released—if required—is contacted with a proteolytic agent and the glycated haemoglobin degradation products obtained in this way or otherwise are quantified is disclosed. In order to provide such a process and reagents employable therein that has/have the property of sufficient stability of the chemical compounds that are essential to the reaction, for the stabilization of the haemoglobin which is unfolded at a very low pH in the range from 1 to 3, at least one suitable stabilizer is present in the haemolysis solution.Type: GrantFiled: May 6, 2015Date of Patent: October 9, 2018Assignee: DiaSys Diagnostic Systems GmbHInventors: Günther Gorka, Yoshifumi Watazu, Erwin Metzmann, Alexandra Lein, Holger Müller, Matthias Grimmler
-
Publication number: 20170191112Abstract: A method for determining the amount of glycated haemoglobin (HbA1c), in which—if required—the erythrocytes in a sample are haemolysed, the haemoglobin that is then released—if required—is contacted with a proteolytic agent and the glycated haemoglobin degradation products obtained in this way or otherwise are quantified is disclosed. In order to provide such a process and reagents employable therein that has/have the property of sufficient stability of the chemical compounds that are essential to the reaction, the provision of the requisite proteolytic agent in the form of an inactivated protease is proposed, which is then only reactivated in situ.Type: ApplicationFiled: March 31, 2015Publication date: July 6, 2017Inventors: Günther GORKA, Yoshifumi WATAZU, Erwin METZMANN, Alexandra LEIN, Holger MÜLLER, Matthias GRIMMLER
-
Publication number: 20170058318Abstract: A method for determining the amount of glycated haemoglobin (HbA1c), in which—if required—the erythrocytes in a sample are haemolysed, the haemoglobin that is then released—if required—is contacted with a proteolytic agent and the glycated haemoglobin degradation products obtained in this way or otherwise are quantified is disclosed. In order to provide such a process and reagents employable therein that has/have the property of sufficient stability of the chemical compounds that are essential to the reaction, for the stabilization of the haemoglobin which is unfolded at a very low pH in the range from 1 to 3, at least one suitable stabilizer is present in the haemolysis solution.Type: ApplicationFiled: May 6, 2015Publication date: March 2, 2017Inventors: Günther GORKA, Yoshifumi WATAZU, Erwin METZMANN, Alexandra LEIN, Holger MÜLLER, Matthias GRIMMLER